What Does a T-Score of -1.9 Mean?
A T-score of -1.9 indicates osteopenia (low bone mass), placing you in the intermediate risk category between normal bone density and osteoporosis, and requires lifestyle modifications plus risk stratification to determine if pharmacological treatment is needed. 1
Understanding Your T-Score Classification
Your T-score of -1.9 falls within the World Health Organization's definition of osteopenia, which encompasses T-scores between -1.0 and -2.5. 2 This means your bone mineral density is 1.9 standard deviations below the average peak bone mass of a healthy young adult. 2
- Normal bone density: T-score ≥ -1.0 2
- Osteopenia (your category): T-score between -1.0 and -2.5 2
- Osteoporosis: T-score ≤ -2.5 2
Immediate Management Steps
Non-Pharmacological Interventions (First-Line for All Osteopenia)
Implement these lifestyle modifications immediately, as they form the foundation of osteopenia management: 3
- Calcium intake: 1,000-1,200 mg daily through diet or supplements 1, 3
- Vitamin D supplementation: 800-1,000 IU daily 1, 3
- Weight-bearing exercise: At least 30 minutes, three or more days per week 3
- Resistance training: Include strength-building exercises 3
- Smoking cessation: If applicable 1, 3
- Alcohol limitation: Reduce intake if consuming ≥3 units daily 3
Risk Stratification Required
You must calculate your 10-year fracture risk using the FRAX algorithm to determine if pharmacological therapy is warranted. 1, 3 The FRAX tool incorporates your T-score along with clinical risk factors including age, sex, body mass index, prior fragility fracture, parental hip fracture history, current smoking status, glucocorticoid use, rheumatoid arthritis, secondary osteoporosis causes, and alcohol consumption. 3
When Pharmacological Treatment Is Indicated
Consider starting medication if your FRAX calculation shows: 1
Also consider treatment if you have: 3
- History of fragility fracture after age 50 (even with osteopenic T-score) 1, 3
- Two or more additional risk factors: maternal hip fracture history, current smoking, BMI <24, or oral glucocorticoid use >6 months 3
- Height loss >4 cm (suggests possible vertebral compression fractures) 1, 3
First-Line Pharmacological Options (If Indicated)
Oral bisphosphonates are the preferred initial therapy: 1
- Alendronate 70 mg once weekly 1
- Risedronate 35 mg once weekly or 150 mg once monthly 3
- Ibandronate 150 mg once monthly 3
- Zoledronic acid 5 mg IV every 2 years 3
- Denosumab 60 mg subcutaneously every 6 months (particularly if bisphosphonates cannot be tolerated) 3
Monitoring Recommendations
Repeat DEXA scan in 1-2 years at the same facility using the same machine to accurately assess progression. 3 A change of 1.1% or greater in bone mineral density is considered clinically significant. 3
Critical Pitfalls to Avoid
Do not start bisphosphonates if you have: 3
- Esophageal abnormalities (stricture, achalasia, hiatal hernia) 1, 3
- Inability to remain upright for ≥30 minutes after taking medication 1, 3
- Hypocalcemia (must correct first) 1
Address calcium and vitamin D deficiency before initiating any pharmacologic therapy. 3 Concomitant proton-pump inhibitor use reduces calcium absorption and independently increases fracture risk, which should factor into your overall risk assessment. 3
If denosumab is ever prescribed, never discontinue it abruptly without transitioning to another antiresorptive agent due to severe rebound bone loss risk. 3
Additional Screening Considerations
You should undergo vertebral fracture assessment (VFA) or spine radiographs if you meet any of these criteria: 1, 3
- Age ≥70 years with T-score <-1.0 1
- Documented height loss >4 cm 1, 3
- Self-reported prior vertebral fracture (not yet confirmed radiographically) 1
- Glucocorticoid therapy ≥5 mg prednisone daily for ≥3 months 1
These criteria identify individuals who may have silent vertebral fractures, which would change your diagnosis to osteoporosis regardless of your T-score and mandate treatment. 1, 3